Pete De Spain brings more than two decades of biotech-focused investor relations and corporate communications experience to Kura, where he oversees both of these key functions. Before joining Kura in 2017, Mr. De Spain served since 2010 as Vice President of Investor Relations and Corporate Communications at MEI Pharma, a publicly held oncology company in San Diego. Previously, he was Director of Investor Relations and Corporate Communications at Prometheus Laboratories, prior to its acquisition by Nestlé Health Science. Earlier roles include investor relations and corporate communications positions at Favrille, a cancer immunotherapy company, Anadys Pharmaceuticals (acquired by Roche), Sequenom (acquired by LabCorp) and Sunrise Medical. Mr. De Spain is a past President of the San Diego chapter of the National Investor Relations Institute (NIRI). He holds a bachelor’s degree in communication with a public relations emphasis from San Diego State University.